Benitec raises $3.75m, launches share purchase plan
Monday, 08 November, 2004
Gene silencing specialist Benitec (ASX:BLT) has raised AUD$2.75 million in a placement to institutions and 'sophisticated' investors in Australia and abroad, the company said today.
And it has opened a share purchase plan to shareholders, offering up to $4950 of fully-paid ordinary shares at $0.55, a 14.9 per cent discount to Benitec's volume-weighted average price over the last five days.
In a statement, the company said it would use the funds raised for a variety of activities, including expanding its US facilities, US management team and RNAi intellectual property, reviewing M&A opportunities, and developing its cancer program.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
